Soo Bang

Lead corporate development and external strategy for a clinical-stage precision oncology company advancing a first-in-class NSD2 inhibitor platform Shape and execute partnership strategy across clinical collaborations, combination regimens, and long-term value creation initiatives; negotiated and closed two strategic clinical supply agreements Influence portfolio and clinical development strategy by integrating KOL insights, competitive intelligence, and cross-functional input across clinical, translational, and medical Establish and leverage a global network of investigators, academic institutions, patient advocacy, and industry partners to accelerate trial enrollment, expand scientific visibility, and position the program for combination opportunities Shape investor narrative and corporate positioning in close partnership with executive leadership, strengthening differentiation and long-term strategic optionality

Innovo Therapeutics is committed to discovering and developing the next generation of protein degraders in areas of high unmet medical need. Our extensive experience in drug discovery, combined with our unique expertise in targeted protein degradation, allows us to quickly develop an extensive compound library of novel and drug-like structures which generates high-quality leads. We have a powerful targeted protein degradation platform called TriNovo. Coupled with a proprietary phenotypic screening platform, our scientists build and rapidly expand a high-quality, differentiated pipeline. Our competitive advantage is a differentiated drug discovery approach, allowing us to advance our pipeline quickly. We continue to drive value through highly validated biology and our differentiated, high-throughput chemistry platform. We focus on execution, rapidly growing our pipeline through corporate and academic alliances. We have worldwide exclusive rights to Rosmantuzumab, anti-RSPO2 mAB, which is a Phase 2 clinical program. We are actively engaged in further pharma partnerships discussion to advance our pipeline programs. We are maximizing Innovo’s expertise, productivity, and efficiency with the Innovo US team’s proven drug discovery experience, leveraging our expertise, and optimizing China’s rich pre-clinical resources and infrastructure to build a world-class, global biopharma company.

I serve as the biotech industry board representative for MedStar Health Research Institute, which provides support for research programs throughout MedStar Health. MedStar Health is a not-for-profit, regional healthcare system with nine hospitals and more than 20 other health-related services in greater Washington DC metro area and academically affiliated with Georgetown University. Governance Committee Chair 2022.

N-Power Medicine, we are a venture-backed startup that aims to establish a new paradigm for speed and certainty in oncology drug development by transforming routine patient care data to clinical trial grade data to accelerate more inclusive industry-sponsored clinical trials.

Biotech/Pharma, Digital Health, Academic/Health Systems Management Consultant specializing in strategy, business development, operations and integration in areas of clinical research, manufacturing, clinical operations and BD/AM. Strategic advisor for C-suite executives for partnering and lead business development and fundraising activities. Lead executive-level discussions, including target partner outreach, pitch preparation and management presentations and due diligence process. Specializes in international and partnering relationships.

Lead the largest biopharma $74 billion integration, planning & operations, board, and leadership communication. Accountable for cross functional integration management teams (IMT) programs, across international markets, enabling functions (HR, IT, Finance) and BUs. Lead global enterprise change champions network, drive complex interdependencies, decision-making and accountability across IMTs.

As Head of Business, Strategy & Integration (BSI) and Product Leadership, I lead and owned the Global Pharmaceutical Development, Operations and Manufacturing Strategic planning process, Project Management Office, Operational Excellence, and Technical Commercial Product leadership functions. My functionally diverse team worked to align the overall strategy, project portfolio and governance with Celgene’s commercial, clinical and manufacturing development strategy, product portfolio and program governance. Through optimization of commercialization strategies and alignment of internal/external stakeholders, BSI supports value creation through collaborative innovation, decision making and planning. Organized and operationalized three new Product Launch readiness teams and management of information to organization. Led late stage oncology asset CMC transition-INREBIC® (Fedratinib); Transition Leader for late stage asset cross functional team (marizomib). Identified life cycle management opportunities, including facilitating decisions for Acceleron developing (sotatercept) for PAH and structure for partnership & transition.

Senior Director 2013-September 2016 Successfully launched and managed over $1B of Celgene's strategic collaboration investments. Led alliances through its life cycle process from diligence, launch, amendments, and termination; a variety of deal structures; option to acquire, asset purchase, collaboration and across oncology, immunology & inflammation franchises, early R&D through medical affairs. Implemented alliance governance, contract management and ensure milestones deliverables. I led late-stage oncology asset acquisition (marizomib - brain penetrant irreversible proteasome inhibitor) and was the transitional Leader for asset (INREBIC) integration team. I am proud to be part of the BD & Global Alliances team that earned Celgene’s reputation as the Partner of Choice in BCG Survey for two consecutive award cycles.

I led a talented global team and provided the strategic vision for all clinical contract activities, including investigator grants, oversee and managed clinical trial site contracts for Celgene sponsored agreements. Collaborated with legal and finance organization to improve processes and tools. Worked with regional and therapeutic heads to optimize site contracting process to meet the corporate MIP targets, and develop new operating model paradigms for partnerships with sites, and CROs. Responsible for ensuring investigator grants fair market value and improved performance metrics and targets for study start-up activities, including implementation of central IRB model.

Contracts and Outsourcing: Investigator agreements, negotiation and modification of Phase II-IV clinical trials agreements and budgets with research sites. Responsible for insuring execution and monitoring of quality of agreements for Medical Affairs (Investigator-initiated research and Publications), Outcomes Research across all Pfizer's business units and Functional Service Providers for Development Operations. Managed and supervised 10 FTEs and 2 contractors. Collaborated and monitored strategic partnership CROs/FSP to ensure timely study start-up activities. Lead global investigator grant cost savings and benchmarking initiatives. Created “Face of Pfizer” with Institutions’ Grants and Contract offices through relationship management initiative to improve site study start up processes. Lead continuous improvement activities by improving Study Start-Up through process reviews and evaluation and alignment with internal and external resources. Lead Lean Six Sigma Green Belt project in improving US academic medical centers contract cycle time and achieved 55% improvement.

Lead instructor for core graduate course in Human Trials II, Drug and Biologic Development and Clinical Research Finance course includes NIH funding, federal cost principles, and industry business practices of clinical research financial management and venture capital financing. Course involves pharmaceutical and project management, clinical development as a product/biologic proceeds from an IND to NDA. • Alpha Eta Honor Society – Outstanding Faculty Honor Award, The George Washington University May 2004

Created a new central office for Clinical and Health Service Research for 11 acute care public hospitals, clinics and long-term care facilities of New York City. Primary responsibilities included establishing policies and providing oversight for all clinical and health service research throughout the Corporation. Lead the Research Oversight Committee. Reviewed and authorized all medical research that is conducted at Corporation facilities to assure compliance with corporate policies including the HHC Clinical Investigation and Research Policy and Guidelines, and federal and state regulations. Served as the Corporation’s liaison to governmental and professional agencies on research matters, and was responsible for seeking additional clinical and health services research grants.

Graduated with special honors in Psychology